{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:50Z","timestamp":1790207750301,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast growth factor receptor 2 (FGFR2) gene fusions are detected in 10%\u201316% of cholangiocarcinomas but are rarely detected in other solid tumours. Herein, we report the case of a 59-year-old woman with stage IVB gastric cancer (UICC 8th edition) characterized by FGFR2-TRIM44 fusion and FGFR2 amplification. Her tumour progressed despite multiple lines of standard chemotherapy. Plasma ctDNA analysis revealed these alterations, and pemigatinib was recommended by an expert panel. Treatment led to a remarkable clinical and radiological response, and she remained on pemigatinib with stable symptoms for 5\u00a0months. According to the C-CAT database, FGFR2 amplification was identified in 4.9%, while FGFR2 fusions were identified in only 0.26% of 3116 oesophagogastric adenocarcinomas, with FGFR2-TRIM44 fusions detected in just 0.064%, including our case. Targeted therapies based on genomic information are limited in the treatment of advanced gastric cancer. Thus, this case suggests that pemigatinib may represent a promising targeted therapy option for patients with advanced gastric cancer harbouring FGFR2 alterations.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf162","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:50:01Z","timestamp":1759837801000},"page":"110-114","source":"Crossref","is-referenced-by-count":3,"title":["Remarkable response of gastric adenocarcinoma with\n                    <i>FGFR2-TRIM44<\/i>\n                    fusion to pemigatinib: a case report"],"prefix":"10.1093","volume":"56","author":[{"given":"Miho","family":"Fujiwara","sequence":"first","affiliation":[{"name":"Department of Allergy and Respiratory Medicine, Okayama University Hospital , Okayama University Hospital, 2-5-1 Shikata-cho Kitaku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2134-2865","authenticated-orcid":false,"given":"Kiichiro","family":"Ninomiya","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital , Okayama University Hospital, 2-5-1 Shikata-cho Kitaku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Chikuie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Science, Hiroshima University Hospital , Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Science, Hiroshima University Hospital , Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Science, Hiroshima University Hospital , Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Makimoto","sequence":"additional","affiliation":[{"name":"Department of Allergy and Respiratory Medicine, Okayama University Hospital , Okayama University Hospital, 2-5-1 Shikata-cho Kitaku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Horiguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Hospital , Okayama University Hospital, 2-5-1 Shikata-cho Kitaku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuta","family":"Tomida","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital , Okayama University Hospital, 2-5-1 Shikata-cho Kitaku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital , Okayama University Hospital, 2-5-1 Shikata-cho Kitaku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital , National Cancer Center Hospital, 5-1-1, Tsukiji, Chuoku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7588-6745","authenticated-orcid":false,"given":"Shinichi","family":"Toyooka","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital , Okayama University Hospital, 2-5-1 Shikata-cho Kitaku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama University, 2-5-1 Shikata-cho Kita-ku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2966-106X","authenticated-orcid":false,"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Center for Clinical Oncology, Okayama University Hospital , Okayama University Hospital, 2-5-1 Shikata-cho Kitaku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"2026012223580543900_ref1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"2026012223580543900_ref2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026012223580543900_ref3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg","year":"2022","journal-title":"Nature"},{"key":"2026012223580543900_ref4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026012223580543900_ref5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/cas.16034","article-title":"Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE trial","volume":"115","author":"Ando","year":"2024","journal-title":"Cancer Sci"},{"key":"2026012223580543900_ref6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/biomedicines12051117","article-title":"Clinical developments and challenges in treating FGFR2-driven gastric cancer","volume":"12","author":"Lau","year":"2024","journal-title":"Biomedicines"},{"key":"2026012223580543900_ref7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10120-017-0758-x","article-title":"In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients","volume":"21","author":"Kuboki","year":"2018","journal-title":"Gastric Cancer"},{"key":"2026012223580543900_ref8","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-21-1414","article-title":"Circulating tumor DNA analysis detects FGFR2 amplification and concurrent genomic alterations associated with FGFR inhibitor efficacy in advanced gastric cancer","volume":"27","author":"Jogo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026012223580543900_ref9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: the national datacenter for cancer genomic medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov"},{"key":"2026012223580543900_ref10","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Cancer Discov"},{"key":"2026012223580543900_ref11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/annonc\/mdx107","article-title":"A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification","volume":"28","author":"Van Cutsem","year":"2017","journal-title":"Ann Oncol"},{"key":"2026012223580543900_ref12","doi-asserted-by":"publisher","first-page":"115262","DOI":"10.1016\/j.ejca.2025.115262","article-title":"Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications","volume":"218","author":"Satoh","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026012223580543900_ref13","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat Med"},{"key":"2026012223580543900_ref14","doi-asserted-by":"publisher","first-page":"9714570","DOI":"10.1155\/2022\/9714570","article-title":"Incidence of FGFR2 amplification and FGFR2 fusion in patients with metastatic cancer using clinical sequencing","volume":"2022","author":"Hyung","year":"2022","journal-title":"J Oncol"},{"key":"2026012223580543900_ref15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026012223580543900_ref16","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1158\/1078-0432.CCR-15-2448","article-title":"c-Myc alteration determines the therapeutic response to FGFR inhibitors","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026012223580543900_ref17","doi-asserted-by":"publisher","first-page":"e2500033","DOI":"10.1200\/PO-25-00033","article-title":"Clinical significance of extrachromosomal DNA in FGFR2-amplified gastric cancer: therapeutic implications from clinical experience","volume":"9","author":"Aoki","year":"2025","journal-title":"JCO Precis Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/1\/110\/64831070\/hyaf162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/1\/110\/64831070\/hyaf162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T04:58:12Z","timestamp":1769144292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/1\/110\/8294288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,21]]},"published-print":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf162","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,21]]}}}